Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Teva Pharmaceutical Industries Ltd

NYSE: TEVA · Life Sciences · 11 alerts · CIK 818686

Share price
$42.57Close, Nov 16
Market cap
$49.7B
Shares outstanding
1.17BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Teva Pharmaceutical Industries Ltd filings on SEC EDGAR ↗

8:09 AM ET 8-K
Financial Results

Teva Pharmaceutical Industries Financial Results

Teva Pharmaceutical Industries reported Q3 2026 revenues of $4.4 billion, a 2% decrease year-over-year due to competition for its generic Revlimid, offset by 33% growth in its innovative brand portfolio. The company raised its full-year 2026 revenue outlook for key brands AUSTEDO, AJOVY, and UZEDY following strong quarterly performance and gross margin expansion.

Term
Q3 2026

“Teva’s Pivot to Growth strategy is delivering strong results, as evidenced by the 33% growth across our key innovative brands and the substantial expansion of our non-GAAP gross profit margin to its highest level in a decade. We are strengthening our neuroscience leadership with the launch of WELTRUZA™ and the strategic addition of BXCL-501, while our biosimilars business is set to achieve its 2027 revenue goal a year ahead of schedule.”

Richard Francis, Teva's President and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.